United Therapeutics Corporation Increase (Decrease) in Prepaid Expense
United Therapeutics Corporation (UTHR) reported Increase (Decrease) in Prepaid Expense of -$5.87 million for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-07-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2013-07-25
- United Therapeutics Corporation increase (decrease) in prepaid expense for the quarter ending 2013-06-30 was -$1.31M, a 133.15% decline year-over-year.
- United Therapeutics Corporation increase (decrease) in prepaid expense for the quarter ending 2013-03-31 was -$4.56M, a 186.81% decline year-over-year.
- United Therapeutics Corporation increase (decrease) in prepaid expense for the quarter ending 2012-12-31 was $3.71M, a 1801.54% increase year-over-year.
- United Therapeutics Corporation increase (decrease) in prepaid expense for the quarter ending 2012-09-30 was -$5.57M.
- United Therapeutics Corporation increase (decrease) in prepaid expense for fiscal 2012 was $7.35M, a 248.88% increase from fiscal 2011.
- United Therapeutics Corporation increase (decrease) in prepaid expense for fiscal 2011 was $2.11M, a 258.94% increase from fiscal 2010.
- United Therapeutics Corporation increase (decrease) in prepaid expense for fiscal 2010 was $587.00K.
- United Therapeutics Corporation increase (decrease) in prepaid expense for fiscal 2009 was -$3.42M, a 160.23% decline from fiscal 2008.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2013-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$5.87M 10-Q · filed 2013-07-25 | -$2.17M derived: sum of 3 quarters · filed 2013-07-25 | -$7.74M derived: sum of 4 quarters · filed 2013-07-25 |
| 2013-03-31 | -$4.56M 10-Q · filed 2013-04-25 | -$853.00K derived: sum of 2 quarters · filed 2013-04-25 | -$6.42M derived: sum of 3 quarters · filed 2013-04-25 | -$2.46M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$1.86M derived: sum of 2 quarters · filed 2013-02-26 | $2.10M derived: sum of 3 quarters · filed 2013-07-25 | $7.35M 10-K · filed 2013-02-26 |
| 2012-09-30 | -$5.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$1.61M derived: sum of 2 quarters · filed 2013-07-25 | $3.64M 10-Q · filed 2012-11-01 | $3.84M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $9.21M 10-Q · filed 2013-07-25 | $9.41M derived: sum of 3 quarters · filed 2013-07-25 | $8.98M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-03-31 | $5.25M 10-Q · filed 2013-04-25 | $5.45M derived: sum of 2 quarters · filed 2013-04-25 | $5.02M derived: sum of 3 quarters · filed 2013-04-25 | $3.26M derived: sum of 4 quarters · filed 2013-04-25 |
| 2011-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$231.00K derived: sum of 2 quarters · filed 2013-02-26 | -$1.99M derived: sum of 3 quarters · filed 2013-02-26 | $2.11M 10-K · filed 2013-02-26 |
| 2011-09-30 | -$426.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$2.19M derived: sum of 2 quarters · filed 2012-11-01 | $1.91M 10-Q · filed 2012-11-01 | $3.01M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $2.34M 10-Q · filed 2012-07-26 | $3.43M derived: sum of 3 quarters · filed 2013-02-26 | $1.78M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $4.10M 10-Q · filed 2012-04-26 | $5.20M derived: sum of 2 quarters · filed 2013-02-26 | $3.54M derived: sum of 3 quarters · filed 2013-02-26 | $4.23M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$556.00K derived: sum of 2 quarters · filed 2013-02-26 | $130.00K derived: sum of 3 quarters · filed 2013-02-26 | $587.00K 10-K · filed 2013-02-26 |
| 2010-09-30 | -$1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$964.00K derived: sum of 2 quarters · filed 2011-10-27 | -$507.00K 10-Q · filed 2011-10-27 | -$451.00K derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-06-30 | $686.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $1.14M 10-Q · filed 2011-07-28 | $1.20M derived: sum of 3 quarters · filed 2012-02-28 | $250.00K derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-03-31 | $457.00K 10-Q · filed 2011-04-28 | $513.00K derived: sum of 2 quarters · filed 2012-02-28 | -$436.00K derived: sum of 3 quarters · filed 2012-02-28 | |
| 2009-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | -$893.00K derived: sum of 2 quarters · filed 2012-02-28 | -$3.42M 10-K · filed 2012-02-28 | |
| 2009-09-30 | -$949.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$3.48M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | -$2.53M 10-Q · filed 2010-07-28 | |||
| 2008-12-31 | $5.68M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |